Form 483

PF Consumer Healthcare BV (Puerto Rico Operations) LLC Form 483, 2021-03-17

FDA issued a Form 483 to PF Consumer Healthcare BV (Puerto Rico Operations) LLC on 2021-03-17 with 5 public-safe observations.

483· Form 483 issuedHuman Drugs5 observations

PF Consumer Healthcare BV (Puerto Rico Operations) LLC · Guayama, United States · Issued March 17, 2021

Overview

  • 5 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

17 Mar 2021
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Jose F Velez, Miguel A Martinez

17 Mar 2021
21 CFR 211.170(b)

Annual visual exams of drug products

Cited by Jose F Velez, Miguel A Martinez

17 Mar 2021
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Jose F Velez, Miguel A Martinez

17 Mar 2021
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Jose F Velez, Miguel A Martinez

17 Mar 2021
21 CFR 314.81(b)(1)(ii)

Failure to meet specifications

Cited by Jose F Velez, Miguel A Martinez

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.170(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 314.81(b)(1)(ii)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 5 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere